Search research articles
Contact Us
Filters
Showing results (141-150 of 190) with videos related to
Page
of 19
Sort By:
The Lancet. Rheumatology
|
January 31, 2024
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial
Roy Fleischmann, Alan Friedman, Edit Drescher, et al.
Rheumatology and Therapy
|
November 24, 2021
Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Philip Conaghan, Stanley Cohen, Gerd Burmester, et al.
Rheumatology and Therapy
|
September 8, 2022
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
Kurt de Vlam, Philip J Mease, Andrew G Bushmakin, et al.
Rheumatology and Therapy
|
January 21, 2026
Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis
Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, et al.
Arthritis and Rheumatism
|
February 10, 2011
The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy
Paul Emery, Roy Fleischmann, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases
|
September 20, 2011
Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
Paul Emery, Désirée van der Heijde, Mikkel Ostergaard, et al.
Arthritis Research & Therapy
|
November 17, 2015
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Michael E Weinblatt, Roy Fleischmann, Ronald F van Vollenhoven, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
July 10, 2019
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Roy Fleischmann, Aileen L Pangan, In-Ho Song, et al.
Clinical Rheumatology
|
August 6, 2018
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
Désirée van der Heijde, Patrick Durez, Georg Schett, et al.
Drugs in Context
|
October 30, 2020
Upadacitinib <i>versus</i> placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients
Karel Pavelka, Zoltán Szekanecz, Nemanja Damjanov, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 190) with videos related to
Sort By:
Page
of 19
The Lancet. Rheumatology
|
January 31, 2024
Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial
Roy Fleischmann, Alan Friedman, Edit Drescher, et al.
Rheumatology and Therapy
|
November 24, 2021
Benefit-Risk Analysis of Upadacitinib Compared with Adalimumab in the Treatment of Patients with Moderate-to-Severe Rheumatoid Arthritis
Philip Conaghan, Stanley Cohen, Gerd Burmester, et al.
Rheumatology and Therapy
|
September 8, 2022
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
Kurt de Vlam, Philip J Mease, Andrew G Bushmakin, et al.
Rheumatology and Therapy
|
January 21, 2026
Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis
Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, et al.
Arthritis and Rheumatism
|
February 10, 2011
The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy
Paul Emery, Roy Fleischmann, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases
|
September 20, 2011
Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis
Paul Emery, Désirée van der Heijde, Mikkel Ostergaard, et al.
Arthritis Research & Therapy
|
November 17, 2015
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Michael E Weinblatt, Roy Fleischmann, Ronald F van Vollenhoven, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
July 10, 2019
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial
Roy Fleischmann, Aileen L Pangan, In-Ho Song, et al.
Clinical Rheumatology
|
August 6, 2018
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study
Désirée van der Heijde, Patrick Durez, Georg Schett, et al.
Drugs in Context
|
October 30, 2020
Upadacitinib <i>versus</i> placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients
Karel Pavelka, Zoltán Szekanecz, Nemanja Damjanov, et al.
Page
of 19